Edwards Lifesciences (EW) Other Non-Current Liabilities (2009 - 2026)

Edwards Lifesciences' Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $350.7 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 1.93% year-over-year to $350.7 million in Q1 2026; TTM through Mar 2026 was $350.7 million, a 1.93% decrease from a year earlier, with the FY2025 full-year figure at $362.3 million, down 2.95% from the prior year.
• Other Non-Current Liabilities slipped to $350.7 million in Q1 2026 per EW's latest filing, from $362.3 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $379.2 million in Q2 2025 and bottomed at $217.5 million in Q4 2022.
• The 5-year median for Other Non-Current Liabilities is $336.6 million (2024), against an average of $307.1 million.
• Across the five-year window, Other Non-Current Liabilities declined 19.75% in 2022 and jumped 48.55% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $217.5 million in 2022, then rose by 15.54% to $251.3 million in 2023, then jumped by 48.55% to $373.3 million in 2024, then retreated by 2.95% to $362.3 million in 2025, then decreased by 3.2% to $350.7 million in 2026.
• Per Business Quant, the three latest EW Other Non-Current Liabilities figures stand at $350.7 million (Q1 2026), $362.3 million (Q4 2025), and $362.6 million (Q3 2025).